Topiramate-Induced Bilateral Acute Angle Closure With Fibrinous Hypopyon Uveitis, Subretinal Fluid, and Late Surgical Sequelae: A Case Report and Focused Literature Review

The human eye is a delicate optical instrument, relying on a precise balance of fluid pressure to keep its internal structures in place and its vision sharp. When this pressure rises too quickly, it can cause a condition known as acute angle closure, where the drainage channels for the eye's fluid become blocked, leading to severe pain, blurred vision, and potential blindness. While this emergency is often caused by the pupil getting stuck in a specific position, there is another, less common mechanism where the eye's internal tissues swell, pushing the lens and iris forward and jamming the drainage system from the inside. This swelling can be triggered by certain medications, a phenomenon that doctors have known about for some time but rarely see in its most extreme forms. Understanding how a common drug can unexpectedly trigger such a complex chain reaction is vital for patient safety, as it highlights that the eye's response to medication can be unpredictable and far more severe than a simple headache or temporary blurriness.

In a detailed report from Prince Sultan Military Medical City in Saudi Arabia, a team of ophthalmologists documented a rare and aggressive case involving a 38-year-old woman who experienced a catastrophic reaction to a medication called topiramate. She had started taking the drug, prescribed for chronic headaches, just two days prior to her emergency visit. Almost immediately, she developed a severe headache, vomiting, and a profound loss of vision in both eyes. When she arrived at the hospital, her vision was so poor she could only count fingers held near her face, and the pressure inside her eyes was dangerously high, measuring 47 and 51 millimeters of mercury, far above the normal range. Examination revealed that the front chambers of her eyes were dangerously shallow, and her corneas were swollen, obscuring the view of the back of her eyes. The medical team quickly identified the cause: the medication had triggered a unique type of swelling in the eye's tissues that pushed the internal structures forward, blocking the fluid drainage.

The immediate response was to stop the medication and begin a rigorous treatment plan to lower the pressure and calm the inflammation. While the pressure in her eyes eventually returned to a safe range within three days, the situation inside her eyes took a dramatic and unexpected turn. Instead of simply clearing up, her eyes developed a severe inflammatory reaction. A dense, fibrinous material, resembling thick scar tissue, began to form in the front of her eyes, accompanied by a small collection of white blood cells known as a hypopyon. This was not a typical infection, as tests for bacteria and other systemic diseases came back negative. The inflammation was so intense that her vision worsened further, dropping to the point where she could barely perceive light in one eye and only see hand movements in the other. Further imaging showed that fluid had also accumulated under the retina at the back of her eyes, a condition that threatened her central vision.

To combat this severe inflammation, the doctors introduced powerful steroid treatments, both in eye drops and as a daily pill, while continuing to manage the eye pressure. Over the following weeks, the intense inflammation slowly subsided, and the fluid under the retina disappeared. However, the damage caused by the initial crisis had left a lasting mark. As the inflammation settled, it had caused extensive scarring and adhesion within the eye. The front and back parts of the eye's internal structures had stuck together, and a cloudy film had formed over the lens, leading to cataracts. The drainage channels, once blocked by swelling, were now permanently narrowed by scar tissue. This meant that even though the initial drug reaction had passed, the eye was left in a state of structural compromise that required further intervention.

Months later, the patient underwent a series of surgical procedures to restore her vision. Surgeons carefully removed the scar tissue and the cloudy lens, replacing it with a clear artificial lens. The outcome was a complete recovery of her vision, with her eyes returning to a sharp 20/25 vision, and her eye pressure stabilizing without the need for daily medication. This case serves as a stark reminder that while many drug side effects are temporary, some can trigger a cascade of events leading to permanent structural damage if not managed with extreme care and long-term monitoring. The report emphasizes that the reaction to topiramate is not just a simple blockage that clears up quickly; it can evolve into a severe inflammatory storm that leaves behind significant scarring and requires complex surgical repair.

The authors of the study also reviewed existing medical literature to place this case in a broader context. They found that while topiramate-induced eye pressure spikes are a known risk, usually resolving within a few days of stopping the drug, this specific patient's experience was unusually severe. Most reported cases involve a temporary blockage that clears with medication, but this patient progressed to severe inflammation, fluid accumulation, and permanent scarring. The review highlighted that while doctors know to stop the drug immediately, the potential for such aggressive, long-term damage is often underestimated. The case underscores the importance of recognizing that the eye's reaction to medication can be idiosyncratic, meaning it is a unique and unpredictable response that does not always follow the standard patterns of recovery.

Ultimately, this report provides a critical lesson for both doctors and patients. It illustrates that the timeline for recovery from a drug-induced eye crisis can be much longer and more complicated than previously thought. The initial pressure spike is only the first chapter; the subsequent inflammation and the resulting scar tissue can pose a greater threat to vision than the pressure itself. By documenting the full journey from the initial drug reaction to the final surgical repair, the authors show that successful outcomes are possible, but they require a vigilant, multi-stage approach that includes stopping the drug, treating the inflammation, and monitoring for delayed structural complications. The story of this patient is a testament to the resilience of the human eye and the importance of precise, timely medical intervention in the face of rare and severe adverse reactions.